Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Pediatr Blood Cancer. 2016 Sep 21;64(4):10.1002/pbc.26263. doi: 10.1002/pbc.26263

Table 1.

In Vitro Activity of IVT CBL0137 against PPTP Cell Lines

Cell Line Histotype rIC50
(µM)		 Panel rIC50
/Line rIC50 		T/C Ymin
%
(Observed)		 Relative In/Out
(Observed
Ymin)1
RD Rhabdomyosarcoma 0.20 1.33 0.00 −100.0%
Rh41 Rhabdomyosarcoma 0.45 0.60 0.00 −100.0%
Rh18 Rhabdomyosarcoma 0.80 0.34 0.19 −99.6%
Rh30 Rhabdomyosarcoma 0.20 1.35 0.00 −100.0%
BT-12 Rhabdoid 0.26 1.06 0.00 −100.0%
CHLA-266 Rhabdoid 0.34 0.80 0.77 −97.1%
TC-71 Ewing sarcoma 0.28 0.98 0.00 −100.0%
CHLA-9 Ewing sarcoma 0.16 1.69 0.00 −100.0%
CHLA-10 Ewing sarcoma 0.45 0.60 0.00 −100.0%
CHLA-258 Ewing sarcoma 0.43 0.63 0.00 −100.0%
SJ-GBM2 Glioblastoma 0.21 1.27 0.01 −99.9%
NB-1643 Neuroblastoma 0.21 1.28 0.01 −100.0%
NB-EBc1 Neuroblastoma 0.61 0.44 0.00 −100.0%
CHLA-90 Neuroblastoma 0.74 0.36 0.02 −99.9%
CHLA-136 Neuroblastoma 0.40 0.67 0.00 −100.0%
NALM-6 ALL 0.26 1.02 0.00 −100.0%
COG-LL-317 ALL 0.16 1.67 0.00 −100.0%
RS4;11 ALL 0.20 1.33 0.17 −98.9%
MOLT-4 ALL 0.13 2.04 0.00 −100.0%
CCRF-CEM (1) ALL 0.31 0.88 0.00 −100.0%
Kasumi-1 AML 0.29 0.94 0.00 −100.0%
Karpas-299 ALCL 0.25 1.07 0.00 −100.0%
Ramos-RA1 NHL 0.49 0.56 0.00 −100.0%
Median 0.28 1.00 0.00 −100.0%
Minimum 0.13 0.34 0.00 −100.0%
Maximum 0.80 2.04 0.77 −97.1%
1

The Relative In/Out (I/O)% values compare the relative difference in final cell number compared with the starting cell number for treated cells and for control cells calculated as follows: (Observed Ymin−Y0)/(100−Y0) if Observed Ymin>Y0; and (Observed Ymin−Y0)/(Y0) if Observed Ymin<Predicted Ymin). Y0 is an estimate of the starting cell number derived from determinations of the doubling time for each cell line. Relative I/O% values range between 100% (no treatment effect) to −100% (complete cytotoxic effect), with a Relative I/O% value of 0% being observed for a completely effective cytostatic agent.